Caribou Biosciences Raises $125M Via Equity Just One Week After Pfizer Invested $25M
Portfolio Pulse from Vandana Singh
Caribou Biosciences has raised $125 million through an upsized underwritten public offering of 19.2 million shares at $6.50 per share. This comes a week after Pfizer invested $25 million in the company. Caribou also reported long-term follow-up data from the dose escalation portion of the ongoing ANTLER Phase 1 trial of CB-010, an allogeneic anti-CD19 CAR-T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma.
July 14, 2023 | 1:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Caribou Biosciences has raised significant capital through equity and has reported positive data from its ongoing trial. However, its shares are down 15.60% in premarket trading.
The capital raised and positive trial data are significant for Caribou Biosciences. However, the drop in share price indicates a negative short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Pfizer recently invested $25 million in Caribou Biosciences. The investment is intended to advance CB-011 development.
Pfizer's investment in Caribou Biosciences is significant, but it's unclear how this news will impact Pfizer's stock in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50